PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Twenty-four high-priority prescribing cascades prioritized in older adults

prescribing cascadesdeprescribingpolypharmacygeriatricsolder adultspotentially inappropriate prescribingprescription sequence symmetry analysisSTOPP/STARTcalcium channel blockerdiureticstatincholinesterase inhibitorcorticosteroidantipsychoticretrospective cohortdrug safety Geriatrics / Geriatric Pharmacy

Background Information

Prioritised prescribing cascades highlight risks in older adults.

Identifying inappropriate prescribing cascades in older adults can help reduce medication-related harm and improve drug safety in this vulnerable population. The study identified 24 high-priority prescribing cascades, with cardiovascular drugs frequently initiating cascades. Notably, iron supplements leading to laxative use had the highest incidence at 11.9%. This list can guide initiatives for deprescribing and policy improvements, targeting high-risk cascades for better medication safety among older adults. Understanding prescribing cascades helps target interventions improving medication safety in older adults.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Rochon PA, Austin PC, Gurwitz JH, Wu W, Matai L, Zhang T, Li Z, Savage RD, Gruneir A, Li J, O'Mahony D, Petrovic M, Cherubini A, Onder G, Sternberg SA, McCarthy LM, Dalton K, Reppas-Rindlisbacher CE, Stall NM, Normand ST, Giannakeas V

Citation: Rochon PA, Austin PC, Gurwitz JH, et al. Exploring high priority potentially inappropriate prescribing cascades in older adults: population level retrospective cohort study. BMJ (Clinical research ed.). 2026;394:e100499. doi:10.1136/bmj-2026-100499

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.